With an article at its website Strategy+Business, and with a 28 page PDF online, Price Waterhouse gives us a February 2018 update on "How precision medicine will transform the pharma and healthcare industries."
The web article is here. The PDF is online here.
The main focus is on interview responses from 100 leaders in the biopharma industry. Barriers were listed as "unstable legal/regulatory framework" and "lack of access to relevant data." Precision medicine requires more "collaboration expertise" than simple pop-the-pill drug development.
The three lead authors are based in Frankfurt, Dusseldorf, and Berlin. Readers interested in a C-level health system view of precision medicine may enjoy a 4-page interview based report by Intel, here.